Cover Image
市場調查報告書

纖維肌痛症治療藥的全球市場 (2015∼2019年)

Global Fibromyalgia Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 335549
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
纖維肌痛症治療藥的全球市場 (2015∼2019年) Global Fibromyalgia Drugs Market 2015-2019
出版日期: 2015年07月15日 內容資訊: 英文 73 Pages
簡介

纖維肌痛症為原因不明的症候群之一,主要的症狀為慢性的肌肉痛、肌肉僵硬等。與關節炎不同,關節、肌肉等組織不會發炎,不過,關節和軟組織產生障礙,還有產生非常沉重的頭痛、倦怠感。女性比男性更容易發病,譬如美國有500萬人18歲以上的患者,其中80∼90%是女性。由於沒有纖維肌痛症專用的診斷方法,並用各種診斷法來判斷是否患該疾病。美國現在認可的治療藥僅3種,以並用止痛藥、抗憂鬱症藥、鎮靜劑、神經渙散藥、肌肉鬆弛劑的非標籤藥物治療方法 (認證外治療方法) 積極進行。全球纖維肌痛症治療藥市場2014∼2019年以0.79%的年複合成長率(CAGR) 預計成長。

本報告提供全球的纖維肌痛症的治療藥市場相關分析,疾病概要和市場基本結構,市場規模趨勢 (今後5年的預測值),化學的分類 (藥物類別) 各、各地區的詳細趨勢,推動、阻礙市場要素與其影響力,主要企業簡介,今後的市場機會等調查評估。

第1章 摘要整理

第2章 簡稱集

第3章 分析範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介 (全3產品)

第5章 市場分析技術

  • 市場分析的流程
  • 分析方法

第6章 簡介

第7章 疾病概要

  • 疾病相關理解
  • 前兆、症狀
    • 疼痛、肌肉僵硬
    • 睡眠障礙
    • 倦怠感
    • 慢性頭痛
    • 其他症狀
  • 流行病學
  • 病理生理學
  • 經濟負擔
  • 新的治療方法

第8章 市場環境

  • 市場概況
  • 市場規模與其預測
  • 美國的纖維肌痛症治療藥市場
  • 歐洲的纖維肌痛症治療藥市場
  • 波特的五力分析

第9章 藥物的各化學分類的市場區隔

  • 全球纖維肌痛症治療藥市場:各化學分類 (今後6年的預測值)
  • 正腎上腺素回收抑制劑
  • GABA類似體 (類比)
  • 其他

第10章 地區區分

  • 全球纖維肌痛症治療藥市場:各地區 (今後6年的預測值)

第11章 購買標準

第12章 開發中產品的組合

  • 開發平台候補藥的主要資訊 (共9件)

第13章 推動市場成長要素

第14章 推動因素與其影響力

第15章 市場課題

第16章 推動因素、課題的影響力

第17章 市場趨勢

第18章 市場趨勢與其影響

第19章 供應商環境

  • 競爭方案
    • 近幾年的主要趨勢
    • 企業合併、收購 (M&A)
  • 主要供應商分析
  • 其他/未來的有力供應商

第20章 主要供應商分析

  • Actavis
    • 主要資料
    • 產業概要
    • 產業區分
    • 各部門的市場收益額
    • 各地區的市場收益額
    • 產業策略
    • 主要資訊
    • SWOT分析
  • Eli Lilly
  • Pfizer

第21章 相關報告

圖表一覽

目錄
Product Code: IRTNTR6480

About Fibromyalgia

According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, fibromyalgia is a syndrome with an unknown cause and chronic pain and muscle tenderness as the major symptoms. Unlike arthritis, it does not cause joint, muscle or other tissue inflammation. However, fibromyalgia is known to cause impairment of joints, soft tissues, and causes significant pain and fatigue. Fibromyalgia affects women more than men. In the US, the condition affects more than 5 million people aged 18 years and above, of which 80-90% are women. There is no particular diagnostic test for detecting fibromyalgia, and physicians undertake differential diagnosis to check the presence of the syndrome. Currently in the US, only three drugs are approved to treat fibromyalgia. Off-label treatment is a popular option to treat fibromyalgia using analgesics, antidepressants, sedatives, neuroleptics, and muscle relaxants.

Technavio's analysts forecast the global fibromyalgia drugs market to grow at a CAGR of 0.79% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global fibromyalgia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of fibromyalgia.

Based on the chemical class of the drugs used to treat fibromyalgia, the market is segmented as follows:

  • Serotonin norepinephrine reuptake inhibitors
  • GABA analogs
  • Others

Technavio's report, the Global Fibromyalgia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts.

This report includes a discussion of the market in the following three regions:

  • Americas: The major countries here are the US, Canada, Mexico, and Brazil
  • EMEA: The major countries here are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: The major countries here are Japan, China, Australia, Singapore, South Korea, and India.

APAC is a major untapped market with many leading vendors in the global fibromyalgia drugs market

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Actavis
  • Eli Lilly
  • Pfizer

Other Prominent Vendors

  • Daiichi Sankyo
  • Innovative Med Concepts
  • Meda
  • Meiji Seika
  • Merck Sharp and Dohme
  • Switch Biotech
  • Theravance
  • Tonix
  • Zynerba Pharmaceuticals

Key Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Key Market Challenge

  • Adverse Events
  • For a full, detailed list, view our report

Key Market Trend

  • Expected Entry of ""Me-too"" Drugs
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Savella
    • 04.1.2. Cymbalta
    • 04.1.3. Lyrica

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

  • 07.1. Understanding the Disease
  • 07.2. Signs and Symptoms
    • 07.2.1. Pain and Muscle Stiffness
    • 07.2.2. Sleep Disturbances
    • 07.2.3. Fatigue
    • 07.2.4. Chronic Headache
    • 07.2.5. Other Symptoms
  • 07.3. Epidemiology
  • 07.4. Pathophysiology
  • 07.5. Economic Burden
  • 07.6. Novel Therapeutic Approach

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Fibromyalgia Drugs Market in US
    • 08.3.1. Market Overview
    • 08.3.2. Market Size and Forecast
  • 08.4. Fibromyalgia Drugs Market in Europe
    • 08.4.1. Market Overview
    • 08.4.2. Market Size and Forecast
  • 08.5. Five Forces Analysis

09. Market Segmentation by Chemical Class of Drug

  • 09.1. Global Fibromyalgia Drugs Market by Chemical Class of Drug 2014-2019
  • 09.2. Serotonin-norepinephrine Reuptake Inhibitors
  • 09.3. GABA Analogs
  • 09.4. Others

10. Geographical Segmentation

  • 10.1. Global Fibromyalgia Drugs Market by Geography 2014-2019

11. Buying Criteria

12. Pipeline Portfolio

  • 12.1. Key Information on Pipeline Candidates
    • 12.1.1. TNX-102 SL
    • 12.1.2. Lyrica CR
    • 12.1.3. DS-5655
    • 12.1.4. TD-9855
    • 12.1.5. IMC-1
    • 12.1.6. Mirtazapine
    • 12.1.7. Flupirtine
    • 12.1.8. SWT06101
    • 12.1.9. ZYN001

13. Market Growth Drivers

14. Drivers and Their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and Their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Major Vendor Analysis 2014
    • 19.2.1. Pfizer
    • 19.2.2. Eli Lilly
    • 19.2.3. Actavis
  • 19.3. Other and Future Prominent Vendors

20. Key Vendor Analysis

  • 20.1. Actavis
    • 20.1.1. Key Facts
    • 20.1.2. Business Description
    • 20.1.3. Business Segmentation
    • 20.1.4. Business Segmentation by Revenue 2012 and 2013
    • 20.1.5. Sales by Geography
    • 20.1.6. Business Strategy
    • 20.1.7. Key Information
    • 20.1.8. SWOT Analysis
  • 20.2. Eli Lilly
    • 20.2.1. Key Facts
    • 20.2.2. Business Overview
    • 20.2.3. Business Segmentation by Revenue
    • 20.2.4. Sales by Geography
    • 20.2.5. Business Strategy
    • 20.2.6. Key Information
    • 20.2.7. SWOT Analysis
  • 20.3. Pfizer
    • 20.3.1. Key Facts
    • 20.3.2. Business Overview
    • 20.3.3. Business Segmentation by Revenue 2014
    • 20.3.4. Business Segmentation by Revenue 2013 and 2014
    • 20.3.5. Geographical Segmentation by Revenue 2014
    • 20.3.6. Business Strategy
    • 20.3.7. Key Developments
    • 20.3.8. SWOT Analysis

21. Other Reports in This Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Epidemiology of Fibromyalgia 2014-2019
  • Exhibit 3: Pathophysiology of Fibromyalgia
  • Exhibit 4: Global Fibromyalgia Drugs Market 2014-2019 ($ millions)
  • Exhibit 5: Global Fibromyalgia Drugs Market: Key Takeaways
  • Exhibit 6: Fibromyalgia Drugs Market in US 2014-2019 ($ millions)
  • Exhibit 7: Fibromyalgia Drugs Market in Europe 2014-2019 ($ millions)
  • Exhibit 8: Global Fibromyalgia Drugs Market by Chemical Class of Drug
  • Exhibit 9: Global Fibromyalgia Drugs Market by Geography 2014
  • Exhibit 10: Fibromyalgia: Pipeline Portfolio
  • Exhibit 11: Major Drivers of Global Fibromyalgia Drugs Market
  • Exhibit 12: Major Challenges in Global Fibromyalgia Drugs Market
  • Exhibit 13: Major Trends in Global Fibromyalgia Drugs Market
  • Exhibit 14: Global Fibromyalgia Drugs Market: Vendor Ranking
  • Exhibit 15: Pfizer: YoY Global Revenue of Lyrica 2010-2014 ($ millions)
  • Exhibit 16: Pfizer: Key Takeaways
  • Exhibit 17: Eli Lilly: YoY Global Revenue of Cymbalta 2010-2014 ($ millions)
  • Exhibit 18: Eli Lilly: Key Takeaways
  • Exhibit 19: Actavis: YoY Global Revenue of Savella 2010-2013 ($ millions)
  • Exhibit 20: Actavis: Key Takeaways
  • Exhibit 21: Global Fibromyalgia Drugs MarketBusiness Segmentation 2013
  • Exhibit 22: Global Fibromyalgia Drugs Market Business Segmentation by Revenue 2012 and 2013 ($ millions)
  • Exhibit 23: Actavis : Sales by Geography ($ millions)
  • Exhibit 24: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 25: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ millions)
  • Exhibit 26: Eli Lilly: Sales by Geography 2013
  • Exhibit 27: Pfizer: Business Segmentation by Revenue 2014
  • Exhibit 28: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 29: Pfizer: Geographical Segmentation by Revenue 2014
Back to Top